ClinicalTrials.gg
CompletedNCT06174584Updated Dec 18, 2023

Comparison of Cow Milk and 15% Hypertonic Saline in the Treatment of Rectal Prolapse in Children

An Early Phase 1 interventional study of Hypertonic saline and Cow Milk in Rectal Prolapse, sponsored by Shaheed Zulfiqar Ali Bhutto Medical University. Completed at 1 site in Pakistan. Open to participants aged 1 Year to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-18.

Sponsored by Shaheed Zulfiqar Ali Bhutto Medical University · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 9 months after the study started (first participant enrolled Feb 2021, registered Nov 2023).
Phase
Early Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
1 Year to 12 Years
Sex
All
01

Study summary

To see the outcome of results of Cow Milk \& Hypertonic Saline in the treatment of Rectal Prolapse in Children

Read the detailed description

Sclerotherapy is the least invasive procedure used in management of grade I/II rectal prolapse, with a success rate of around 80%, and generally considered as the first choice for uncomplicated and recurrent prolapse. Several sclerosing agents such as 15% hypertonic saline, 5% Phenol in almond oil and cow milk have been used and reported in the literature. Present study is designed to determine the efficacy of cow milk and 15% hypertonic saline in the management of children with grade I/II rectal prolapse.

All the details will be entered on the proforma which will include resolvement of rectal prolapse and which agent has adverse effects like recurrence, fecal incontinence and anal stenosis.

02

Conditions studied

  • Rectal Prolapse

Browse trials for

03

In context

Rectal Prolapse

55 studies on the registry are indexed under Rectal Prolapse; 12 are open to participants now.

This study's enrollment of 80 is above the median of 55 across 34 interventional studies indexed under Rectal Prolapse.

Browse Rectal Prolapse studies →

Lead sponsor

Shaheed Zulfiqar Ali Bhutto Medical University is the lead sponsor of 37 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All children with Grade I and II rectal prolapse
  • Age \<12 years
  • Both genders

Exclusion criteria

Exclusion Criteria:

  • Rectal prolapse secondary to causes like ulcerative colitis and crohn's disease
  • Past surgical history on the pelvic floor,
  • Neurological diseases like rectal polyps, congenital megacolon, Hirschsprung disease, sacrococcygeal teratoma, neural tube defects, cauda equina syndrome
  • Where parents are not willing to participate in the study
05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
80 participants (actual)

Study arms

  • Active comparator
    Cow Milk

    Cow Milk was injected as sclerosing agent in one group

    Other: Cow Milk

  • Active comparator
    15% Hypertonic Saline

    Hypertonic Saline 15% used as sclerosing agent in other half.

    Drug: Hypertonic saline

Interventions

  • DrugHypertonic saline

    Hypertonic saline

  • OtherCow Milk

    Cow Milk

06

What researchers measure

Primary outcomes

  1. recurrence (as described by parent s during follow up)

    Comparison of Cow Milk vs 15% Hypertonic Saline for rectal prolapse

    Time frame: 1 year

  2. Number of participants with fecal incontinence (as described by parents during follow up)

    Comparison of Cow Milk vs 15% Hypertonic Saline for rectal prolapse

    Time frame: 1 year

  3. Number of participants with anal stenosis (on clinical examination)

    Comparison of Cow Milk vs 15% Hypertonic Saline for rectal prolapse

    Time frame: 1 year

07

Study locations

1 site
  • Shaheed Zulfiqar Ali Bhutto Medical University/PIMS
    Islamabad, 44000, Pakistan
08

References and documents

Individual participant data

Plan to share: No — Confidentiality

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06174584
Lead sponsor
Shaheed Zulfiqar Ali Bhutto Medical University
Responsible party
Mansoor Ahmed (Principal Investigator, Shaheed Zulfiqar Ali Bhutto Medical University) — Principal investigator
First posted
Dec 18, 2023
Start date
Feb 1, 2021
Primary completion
Jan 30, 2022
Completion
Feb 1, 2022
Last update
Dec 18, 2023

Study contacts

Mansoor Ahmed, MBBS
principal investigator · Shaheed Zulfiqar Ali Bhutto Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion